Ro 28-1675

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522523

CAS#: 300353-13-3

Description: Ro 28-1675 is a potent allosteric GK activator with a SC1.5 value of 0.24± 0.0019 uM. Ro 28-1675 reduced fasting and postprandial glucose levels following an OGTT, was well tolerated, and displayed no adverse effects related to drug administration other than hypoglycemia at the maximum dose (400 mg).

Chemical Structure

RO 28-1675

CAS# 300353-13-3

Instruction

Theoretical Analysis

MedKoo Cat#: 522523
Name: RO 28-1675
CAS#: 300353-13-3
Chemical Formula: C18H22N2O3S2
Exact Mass: 378.11
Molecular Weight: 378.510
Elemental Analysis: C, 57.12; H, 5.86; N, 7.40; O, 12.68; S, 16.94

Price and Availability

Size	Price	Availability	Quantity
1g	USD -1
2g	USD -1
5g	USD -1
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: RO28-1675; RO-28-1675; RO 28-1675; RO028-1675; RO-028-1675; RO 028-1675; RO281675; RO 281675; RO-281675; Ro 0281675; Ro-0281675; Ro0281675.

IUPAC/Chemical Name: (2R)-3-Cyclopentyl-2-[4-(methanesulfonyl)phenyl]-N-(thiazol-2-yl)propionamide

InChi Key: NEQSWPCDHDQINX-MRXNPFEDSA-N

InChi Code: InChI=1S/C18H22N2O3S2/c1-25(22,23)15-8-6-14(7-9-15)16(12-13-4-2-3-5-13)17(21)20-18-19-10-11-24-18/h6-11,13,16H,2-5,12H2,1H3,(H,19,20,21)/t16-/m1/s1

SMILES Code: O=C(NC1=NC=CS1)[C@@H](C2=CC=C(S(=O)(C)=O)C=C2)CC3CCCC3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 378.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Roma LP, Duprez J, Jonas JC. Glucokinase activation is beneficial or toxic to cultured rat pancreatic islets depending on the prevailing glucose concentration. Am J Physiol Endocrinol Metab. 2015 Oct 1;309(7):E632-9. doi: 10.1152/ajpendo.00154.2015. Epub 2015 Aug 11. PubMed PMID: 26264555.

2: Al-aryahi S, Kamato D, Getachew R, Zheng W, Potocnik SJ, Cohen N, Guidone D, Osman N, Little PJ. Atherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscle. Cardiovasc Diabetol. 2014 Apr 15;13:80. doi: 10.1186/1475-2840-13-80. PubMed PMID: 24731772; PubMed Central PMCID: PMC4016772.

3: Assefa Z, Lavens A, Steyaert C, Stangé G, Martens GA, Ling Z, Hellemans K, Pipeleers D. Glucose regulates rat beta cell number through age-dependent effects on beta cell survival and proliferation. PLoS One. 2014 Jan 9;9(1):e85174. doi: 10.1371/journal.pone.0085174. eCollection 2014. PubMed PMID: 24416358; PubMed Central PMCID: PMC3887027.

4: Huo LC, Zhang YL, Lei L, Liu SN, Shen ZF, Wang YL, Song HR, Feng ZQ. [Salicylic acid derivatives as simplified and novel GK small molecule activators]. Yao Xue Xue Bao. 2013 Apr;48(4):514-20. Chinese. PubMed PMID: 23833938.

5: Pal M. Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes. Curr Med Chem. 2009;16(29):3858-74. Review. PubMed PMID: 19747136.

6: Wu CF, Xu Y, Tao Y, Yang JY. Establishment of hypoglycemic agent screening method based on human glucokinase. Biomed Environ Sci. 2009 Feb;22(1):62-9. doi: 10.1016/S0895-3988(09)60024-6. PubMed PMID: 19462690.

7: Kumari V, Li C. Comparative docking assessment of glucokinase interactions with its allosteric activators. Curr Chem Genomics. 2008 Dec 30;2:76-89. doi: 10.2174/1875397300802010076. PubMed PMID: 20161845; PubMed Central PMCID: PMC2803441.

8: Li YQ, Feng ZQ, Song HR, Guo YS, Guo ZR. [Advances in the study of glucokinase and small molecule glucokinase activators]. Yao Xue Xue Bao. 2006 May;41(5):390-4. Review. Chinese. PubMed PMID: 16848312.

9: Sarabu R. Anglo-Swedish Medicinal Chemistry - second symposium. IDrugs. 2005 May;8(5):384-6. PubMed PMID: 15883916.

10: McKerrecher D, Allen JV, Bowker SS, Boyd S, Caulkett PW, Currie GS, Davies CD, Fenwick ML, Gaskin H, Grange E, Hargreaves RB, Hayter BR, James R, Johnson KM, Johnstone C, Jones CD, Lackie S, Rayner JW, Walker RP. Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2103-6. PubMed PMID: 15808477.

11: Al-Hasani H, Tschöp MH, Cushman SW. Two birds with one stone: novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism. Mol Interv. 2003 Oct;3(7):367-70. Review. PubMed PMID: 14993457.

12: Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003 Jul 18;301(5631):370-3. PubMed PMID: 12869762.

Your view history